Clinical Trials

18 enrolled

Pancreatic Neoplasms

NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Phase 1 Completed

15 enrolled 21 charts

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06083454 2026-03-13

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

1 enrolled

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07391670 2026-03-12

IMFINZI-subQ

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

20 enrolled

Gastroesophageal Adenocarcinoma

NCT05514132 2026-03-09

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

14 enrolled

Other solid neoplasm

Advanced Solid Tumours

NCT06963346 2026-03-09

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Phase 1 Suspended

12 enrolled

Urinary Bladder Neoplasms

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

184 enrolled

Bites and Stings, Lung Neoplasms

NCT05403723 2026-02-19

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Phase 1 Suspended

50 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03819465 2026-02-11

MAGELLAN

175 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05443971 2026-02-06

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Phase 1 Terminated

4 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06898957 2026-02-05

(DeLLphi-310)

200 enrolled

Phase 1 Not yet recruiting

Small Cell Lung Carcinoma

NCT07107750 2026-02-04

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

48 enrolled

Biliary Tract Neoplasms

NCT02143466 2026-01-30

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

344 enrolled

Advanced Non Small Cell Lung Cancer

NCT05154994 2026-01-27

RESOLVE

9 enrolled

Carcinoma, Transitional Cell

NCT05155189 2026-01-21

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

72 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

50 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03923270 2026-01-08

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

25 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06124118 2026-01-08

NOVOCURE

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06077500 2026-01-06

DAREONᵀᴹ-8

45 enrolled

Small Cell Lung Carcinoma

NCT02546661 2025-12-29

BISCAY

117 enrolled

Muscle Invasive Bladder Cancer

NCT06218511 2025-12-22

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

10 enrolled

Carcinoma, Hepatocellular

NCT04550104 2025-12-19

CONCORDE

200 enrolled